» Articles » PMID: 30368555

High Expression of CCL2 in Tumor Cells and Abundant Infiltration with CD14 Positive Macrophages Predict Early Relapse in Breast Cancer

Overview
Journal Virchows Arch
Date 2018 Oct 29
PMID 30368555
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Macrophages are important for the function of the innate immune system, and in solid tumors, they represent a significant proportion of the tumor mass. Tumor-associated macrophages (TAM) have a M2 phenotype and show a multitude of pro-tumoral functions, promoting tumor cell survival, proliferation, and dissemination. CCL2, synthesized by tumor and stromal cells, initiates a chemokine cascade inducing these processes. We studied by immunohistochemistry (IHC) the frequency of TAMs and CCL2 expressing cells in three groups of primary tumor (PT)-recurrence (R) pairs, where relapse was recorded within 2 years (group 1), between 5 and 10 years (group 2), and after 10 years (group 3). In our study all established breast cancers were heavily infiltrated by CD68 positive cells. Both in PTs and in R lesions the infiltration was more abundant in the peritumoral than in the intratumoral stroma. The mean frequency of M2 marker and CD14 positive cells in the intratumoral stroma and CCL2 expressing tumor cells was higher in the Rs as compared to the corresponding PTs. In PTs, a high frequency of CD14 positive cells and a high expression of CCL2 by tumor cells was associated with an early recurrence. The findings support the current understanding of immune cell orchestrated development, progression and metastatic spread of breast cancer. Our study showed that a high frequency of CCL2 positive tumor cells and CD14 positive TAMs are significant risk factors for rapid tumor recurrence. Potential targets for intervention are discussed.

Citing Articles

Circulating CD3CD8 T Lymphocytes as Indicators of Disease Status in Patients With Early Breast Cancer.

Chen H, Chen Y, Chung W, Loh Z, Lee K, Hsu H Cancer Med. 2025; 14(1):e70547.

PMID: 39749673 PMC: 11696249. DOI: 10.1002/cam4.70547.


FGFR‑related phenotypic and functional profile of CAFs in prognostication of breast cancer (Review).

Solek J, Braun M, Sadej R, Romanska H Int J Oncol. 2024; 65(4).

PMID: 39219285 PMC: 11374155. DOI: 10.3892/ijo.2024.5682.


Multi-Drug Resistance and Breast Cancer Progression via Toll-Like Receptors (TLRs) Signaling.

Pallathadka H, Khaleel A, Zwamel A, Malathi H, Sharma S, Rizaev J Cell Biochem Biophys. 2024; 82(4):3015-3030.

PMID: 39110298 DOI: 10.1007/s12013-024-01418-2.


CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy.

Pant A, Hwa-Lin Bergsneider B, Srivastava S, Kim T, Jain A, Bom S Oncoimmunology. 2024; 13(1):2338965.

PMID: 38590799 PMC: 11000615. DOI: 10.1080/2162402X.2024.2338965.


M1 macrophages polarized by crude polysaccharides isolated from Auricularia polytricha exhibit anti-tumor effect on human breast cancer cells.

Nilkhet S, Mongkolpobsin K, Sillapachaiyaporn C, Wongsirojkul N, Tencomnao T, Chuchawankul S Sci Rep. 2024; 14(1):8179.

PMID: 38589471 PMC: 11001921. DOI: 10.1038/s41598-024-58208-2.


References
1.
Rothenberg M, Pollard J . Postnatal mammary gland development requires macrophages and eosinophils. Development. 2000; 127(11):2269-82. DOI: 10.1242/dev.127.11.2269. View

2.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A . Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23(11):549-55. DOI: 10.1016/s1471-4906(02)02302-5. View

3.
Pollard J . Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4(1):71-8. DOI: 10.1038/nrc1256. View

4.
Frow E, Reckless J, Grainger D . Tools for anti-inflammatory drug design: in vitro models of leukocyte migration. Med Res Rev. 2004; 24(3):276-98. DOI: 10.1002/med.10062. View

5.
Conti I, Rollins B . CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol. 2004; 14(3):149-54. DOI: 10.1016/j.semcancer.2003.10.009. View